大肠癌术前血清CEA、CRP联合检测的临床价值

目的 探讨大肠癌术前血清ＣＥＡ、ＣＲＰ联合检测的临床价值。方法 对２９７例大肠癌患者测定其ＣＥＡ、ＣＲＰ,从病理分期、癌肿部位和手术方式方面进行研讨。结果 联合检测的总阳性率为９０．５７％,明显高于单项检测者：两项阳性者与手术方式有密切关系：右半结肠癌与左半结肠癌直肠癌的ＣＲＰ阳性率和均值相比,差异明显。结论 术前血清ＣＥＡ、ＣＲＰ联合检测具有显著的互补性和临床实用价值。     

胆汁泡蛋白ELISA检测法的建立与初步临床应用

目的 建立胆汁泡蛋白快速检测法,筛选有效的胆石症防治手段。方法 获取３３．５ｋｄ胆汁泡蛋白,通过微量抗原免疫法获得高效价抗体,建立ＥＬＩＳＡ标准曲线;并应用ＥＬＩＳＡ法测定正常人、胆石症患者胆汁和血清中泡蛋白含量,同时观察不同溶石防药和利胆冲剂、胆酸钠等对泡蛋白的影响。结果 建立了ＥＬＩＳＡ标准曲线,其曲线方程为Ｙ＝０．０３５Ｘ（ｒ＝０．９９）;正常人胆汁和血清中３３．５ｋｄ泡蛋白含量都明显较胆固     

PCR辅助转录滴定系统定量检测AFP mRNA方法的建立

目的：建立ＰＣＲ辅助转录滴定系统（ＰＡＴＴＹ）定量检测ＡＦＰ ｍＲＮＡ的方法。方法：采用ＲＴ－ＰＣＲ定点替代突变及体外转录技术合成单碱基突变ＡＦＰ ｍＲＮＡ内竞争模板,以竞争性ＲＴ－ＰＣＲ定量检测各肝癌细胞株ＡＦＰ ｍＲＮＡ,结果：成功制备引入ＨｉｎｄⅢ酶切位上为的单碱基突变ＡＦＰ ｍＲＮＡ内竞争模板,建立ＰＡＴＴＹ定量检测ＡＦＰ ｍＲＮＡ的方法;检测１μｇＨｅｐＧ２和Ｈｕｈ７两株肝癌细胞总ＲＮＡ     

慢性特发性荨麻疹患者血清组胺释放活性的检测

目的 检测慢性特发性荨麻疹患者血中组胺释放活性。方法 自身血清皮肤试验和嗜好性粒细胞组胺释放试验。结果 自身血清皮肤试验和嗜碱性组胺释放试验的阳性率分别为３７．５％和４３．７５％。结论部分慢性特发性荨麻疹患者血中组胺释放活性增高,揭示该类病人具有特殊的肥大细胞和嗜碱性粒细胞激活机制,很可能与自身免疫有关。     

ATP生物发光法检测卵巢癌细胞对化疗药物的敏感性

目的 探讨ＡＴＰ生物发光法药物敏感试验在卵巢癌中的应用的可行性。方法 以ＡＴＰ生物发光法检测卵巢癌ＨＯ－８９１０细胞对１１种常用化疗药物的敏感性,并与ＭＴＴ法相比较。结果 ＡＴＰ浓度、细胞浓度的对数与发光强度（ＲＬＵ）的对数值之间有较好的线性关系,并存在直线回归关系。两种方法测定的抑制率基本符合,但ＡＴＰ法测定的抑制率数值大,变异系数小,结果稳定。结论 ＡＴＰ生物发光法是一种高度敏感的化疗药物敏感     

不同实体瘤体外药敏试验的可行性研究

目的：研究体外药敏试验用于不同原代培养肿瘤细胞的可行性,方法：采用MTT比色分析法,结果：非小细胞肺癌,食管癌,贲门癌对乐铂均较敏感,不同病理类型和同一类型的不同个体对乐铂的敏感性差异较大,且其抑制作 病理类型无密切关系。结论：MTTI地操作简便,快捷,敏感,可应用于实体瘤临床个体化的药敏检测。     

MTT显色反应实验条件分析

目的 :检验分析MTT实验方法本底高、灵敏度低、稳定性差的影响因素 ,改进实验条件提高灵敏度和稳定性 ,降低本底。方法 :用MTT比色方法 ,细胞毒试验及细胞增殖实验 ,分析比较不同条件下MTT显色反应的性能特点。结果 :比较了 13种溶剂对Formazan的溶解性能。分析检验了琥珀酸脱氢酶在细胞上的分布特点、pH值对MTT反应体系的影响、酚红和牛血清对检验结果的影响 ,提出相应对策。检测了MTT反应时间曲线和细胞活力曲线。分析了改进后的MTT实验方法的灵敏度和稳定性。结论 :以MTT为底物的酶在细胞代谢中主要分布在细胞膜表面。MTT反应体系的pH值为 6 7,比较好的Formazan溶剂是正丙醇、异丙醇和乙二醇乙醚。去掉细胞培养上清 ,检测细胞上的酶 ,用溶剂使蛋白质变性 ,经沉淀去掉蛋白质影响 ,能使MTT实验方法的本底降低 ,灵敏度提高。通常情况下该方法检测K 5 62细胞和人淋巴细胞的灵敏度分别为 10 0 0和 10 0 0 0个细胞左右。     

胃癌细胞肿瘤坏死因子受体的研究

目的　探讨人胃癌细胞肿瘤坏死因子受体 ( TNFR)的数目与胃癌细胞分化程度以及与肿瘤坏死因子突变体 ( TNF- m)细胞毒效应之间的关系。方法　以12 5I- TNF- m为配体 ,用放射配体结合分析法 ,检测了高、中、低不同分化程度的体外培养胃癌细胞 ( MKN2 8、SGC790 1、MKN4 5)的 TNFR,同时用 MTT比色法研究了 TNF- m对三株胃癌细胞的细胞毒效应。结果　三株胃癌细胞 TNFR数目分别为每细胞 9.8× 10 -12 nmol、5.6× 10 -12 nmol、3.2× 10 -12 nmol,三者之间比较 ,TNFR数目差异有显著性 ( P<0 .0 5)。解离常数基本一致 ,同一温度时三株胃癌细胞 TNF- m的内化率几乎相等 ,且呈温度依赖关系。TNFR的半衰期大约为 90分钟 ,胞膜与胞浆 TNFR数目之比约为 1∶ 2 ,TNF- m对三株胃癌细胞的最大杀伤率分别为 86%、60 %、34 % ,差异有显著性 ( P<0 .0 5) ,且 39℃时的杀伤率高于37℃时的杀伤率。结论　胃癌细胞表面 TNFR数目与胃癌分化程度相关。 TNF- m的细胞毒效应与TNF数目及 TNF- m的内化量有关。     

Studies of effects of anticancer agents in combination with/without hyperthermia on metastasized human bladder cancer cells in chick embryos using the polymerase chain reaction technique

Cultivated T24 cells derived from a human bladder cancer were inoculated into the chorioallantoic membrane vein of chick embryos. Hyperthermic treatment was performed following injection of anticancer agents 3 days after the inoculation of the T24 cells. DNA samples were obtained from the livers of the chick embryos, and the polymerase chain reaction technique was used to amplify a DNA fragment specific to the human -globin gene. The Southern hybridization method was used to evaluate the inhibitory effects of anticancer agents in combination with/without hyperthermia on T24 cells metastasized to the liver. The hyperthermia exerted an inhibitory effect on the growth of the T24 cells in the livers of the chick embryos, and this was dependent on the thermal dose. The antitumor effects of hyperthermia performed at 42.5° C for 20 min and at 43.0° C for 10 min were evidenced by 69.2% an 82.0% inhibition of the growth of the metastasized T24 cells, respectively, as compared with the growth of untreated T24 cell. Hyperthermia performed at 42.5° C for 10 min alone produced 26.7% tumor growth inhibition, and these conditions for hyperthermia were subsequently used as a criterion for evaluating the effects of its combination with various anticancer agents. Adriamycin (20 g/egg) alone, mitomycin C (10 g/egg) alone, carboplatin (10 g/egg) alone, and cisplatin (10 g/egg) alone produced 13.5%, 58.9%, 27.3%, and 29.1% tumor growth inhibition, respectively. Adriamycin and mitomycin C applied in combination with hyperthermia showed additive inhibitory effects on the growth of the metastasized T24 cells in this chick embryo model.     

Inhibitory effects of adhesion oligopeptides on the invasion of squamous carcinoma cells with special reference to implication of αv integrins

We studied invasion-related adhesion events in vitro using three squamous carcinoma cell lines (HSC-3, poorly differentiated type; OSC-19, well-differentiated type; and KB cells, undifferentiated type). An in vitro invasion assay through matrigel in the transwell chamber revealed that HSC-3 cells were most invasive, OSC-19 cells moderately invasive and KB cells least invasive. Inhibition assay of invasion using synthetic peptides RGD, RGDV, RGDS, RGDT, IKVAV and YIGSR, showed that invasion of the three cell lines was significantly inhibited by RGDV. There were other peptides that inhibited invasion significantly including IKVAV for HSC-3, and RGDS and YIGSR for OSC-19. HSC-3 cells and OSC-19 cells adhered to fibronectin, laminin, vitronectin, and type IV collagen, and KB cells did not adhere to laminin but did to fibronectin, vitronectin and collagen type IV. Pretreatment of cells with RGDV peptide in the attachment assay reduced the ability of these cells to bind to vitronectin and fibronectin more efficiently than pretreatment with RGDS. Anti-v antibodies inhibited adhesion of HSC-3, OSC-19 and KB cells to vitronectin, but anti-1 antibodies did not inhibit adhesion. Immunofluorescent microscopic examinations showed that all cell lines were positive for anti-5 and anti-v antibodies, and only HSC-3 cells were positive for anti-3 antibody. 51 was not clearly demonstrated in any of the cell lines. RGDV was the most effective inhibitor of squamous cell carcinoma invasion among the synthetic oligopeptides used in this experiment, and it is suggested that it affects v3-and/or v5-mediated carcinoma cell invasion.Abbreviations BSA bovine serum albumin - MEM Eagle's minimal essential medium - MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide - PBS phosphatebuffered saline - FITC fluorescein isothiocyanate This work supported in part by a grant from the Osaka Cancer Research Foundation